Abstract 443P
Background
The low survival rate of cancer patients, especially patients who got metastases, necessitates an approach in providing additional therapy that is safe, capable of delaying disease progression, and prolonging patient survival. Vitamin D is an adjunctive therapy that is easy to obtain and shows anti-neoplastic activity against cancer so that it can reduce mortality. This study aimed to conduct a systematic review and meta-analysis regarding the efficacy of vitamin D supplementation in overall survival (OS) of cancer patients.
Methods
A systematic search of various databases up to end of 2022 was conducted to identify Randomized Controlled Trials (RCTs) involving the efficacy of vitamin D supplementation in OS of cancer patients. By using a random effect model, pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated to determine the values of OS. In formulating the study problem, we determine the study questions based on the study background, which consists of the populations (P), interventions (I), comparisons (C), and outcomes (O). The populations were cancer patients. The intervention was administration of vitamin D supplementation. The comparison was no administration of vitamin D supplementation. The outcome was OS. The RCTs having cancer patients over 18 years of age with available and sufficient information about OS were the inclusion criteria of this study. Study that has participants taking vitamin D supplementation regularly, and ongoing study with results not presented or published at the time of the literature search were the exclusion criteria of this study.
Results
Of the six RCTs, analysis was performed on 1,916 cancer patients in this study. In terms of survival, statistically, there was no difference in OS [HR 0.97, 95% CI 0.74 – 1.28, p = 0.85] between vitamin D supplementation and no supplementation in cancer patients.
Conclusions
Although vitamin D supplementation does not improve OS in cancer patients, is could be considered because it still shows benefits for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Internal Medicine, Faculty of Medicine, Sam Ratulangi University / Prof. dr. R. D. Kandou General Hospital, Manado, Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract